Gadeta gadeta.nl


Public list: Pharma Startups (4733) Cancer Therapeutics (1136)

Gadeta has developed a technology platform based on combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta (γδ) T-cell receptors (TCRs) with an enhanced anti-cancer reactivity. Gadeta's new cell-based anti-cancer product called T Cells Engineered To Express A Defined Gamma Delta TCR (TEGs) has strong therapeutic potential for combating and eradicating both hematological and solid tumors. This approach utilizes high-affinity γδ TCRs expressed on αβ T cells with superio...Show all

Gadeta has developed a technology platform based on combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta (γδ) T-cell receptors (TCRs) with an enhanced anti-cancer reactivity. Gadeta's new cell-based anti-cancer product calle...Show all

Company (Acquired)

Phone: +31 (0) 85 016 44 66

Fax:

Yalelaan 62

Ultrecht, 3584
Netherlands

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Gadeta $7.8M Jul 19, 2018

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Gadeta Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 3 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Gamma 9 delta 2 t cell receptors Mar 28, 2013 Feb 13, 2018 Patent
Combinatorial gamma 9 delta 2 t cell receptor chain exchange Dec 09, 2016 Application